Tessel Biosciences

Executive Summary

Tessel Biosciences is a private biotechnology company founded in 2020 that combines AI/ML with patient-derived organotypic tissue models to accelerate drug discovery in tissue remodeling diseases, initially targeting chronic lung conditions. Its proprietary Tesselogic platform integrates high-content physiological phenotyping with active learning algorithms to map molecular states to tissue function, enabling more predictive target identification and validation. The company aims to address the high failure rates in pulmonary drug development by providing insights into disease mechanisms and drug effects in human-relevant models, potentially shortening development timelines and increasing success rates. As a preclinical-stage entity, Tessel Biosciences has not yet disclosed specific pipeline candidates or funding rounds. However, its platform approach positions it as a potential partner for larger pharmaceutical companies seeking to enhance their respiratory portfolios or validate novel targets. The company operates in the competitive AI-driven drug discovery space but differentiates itself through its focus on functional tissue readouts. Key upcoming catalysts include potential Series A financing, strategic partnerships, and publication of platform validation data, which could validate the technology and drive further investment.

Upcoming Catalysts (preview)

• Q4 2026Series A or B Financing Round70% success
• H1 2027Pharmaceutical Partnership for Lung Disease Targets50% success
• Q2 2026Publication of Tesselogic Platform Validation in Peer-Reviewed Journal80% success